B Cell Lymphoma
From the Journals
SOX11 shows value as diagnostic marker in MCL
The meta-analysis evaluated the diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma.
From the Journals
Acalabrutinib may outperform other targeted therapies in MCL
The drug showed advantages over targeted monotherapies but was similar to rituximab-based combinations.
News from the FDA/CDC
FDA approves acalabrutinib for CLL, SLL treatment
The approval was made as part of Project Orbis, a collaboration among the FDA, the Australian Therapeutic Goods Administration, and Health Canada...
From the Journals
Frontline ibrutinib saves money over chemoimmunotherapy
An analysis of claims data for more than 1,000 patients with chronic lymphocytic leukemia shows that ibrutinib monotherapy is a less expensive...
From the Journals
Rituximab maintenance has a durable benefit in follicular lymphoma
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
From the Journals
CAR T-cell ‘cocktail’ may overcome antigen escape relapse
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
From the Journals
Adding polatuzumab extends survival in relapsed/refractory DLBCL
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.
News from the FDA/CDC
FDA approves Brukinsa for relapsed, refractory MCL
The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib showed high overall response rates in two clinical trials.
From the Journals
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...